Sartorius Stedim Biotech shares approach their €228.40 resistance and eye a breakout
The bioprocessing specialist is gaining in mid-afternoon trading on a slightly higher Paris market. The move places it near the top of the index, while analysts continue to scrutinise its valuation after a rally lasting several months.
A share price returning to test its resistance after a solid third quarter
The Sartorius Stedim Biotech share price is at €226.40, up 1.43% from the previous close, among the strongest gainers in the SBF 120.
The stock is less than 1% below the €228.40 resistance, which it broke above and then gave up on November 12. This rise extends a favourable quarter, with a 22.05% gain over three months, and the price remains well above its moving averages: the gap is 2.17% with the 20-day moving average at €221.60 and 23.01% with the 200-day moving average at €184.05.
The RSI at 60 remains neutral. On the fundamentals, the group had published its results for the first nine months of 2026 on October 22, with operating activity up 7.8% at constant exchange rates and targets confirmed. It then expressed increased confidence for the end of the year and highlighted 10.6% growth in Asia-Pacific.
A valuation of 45.5 times expected earnings and geopolitical risks cited
According to the consensus of the analysts covered, the stock trades at around 45.5 times earnings for the current financial year and 37.4 times those of the following year. For shareholders who wish to follow this analyst opinion, this level of valuation remains a central benchmark.
When the nine-month results were published, management cited among the risks the heightened volatility of the sector, geopolitical tensions and the growing weight of trade policy. It also mentioned recurring consumables and a new single-use bioreactor bag as growth drivers.
The last technical level to note is this €228.40 resistance, with a lower support at €208.